Revenue $4.98B, down 9.5% on a year earlier. International Revenues $1.90B, down 18.3%. U.S. revenues $3.08B, down 3.1%. Diluted EPS $1.37 against $2.00.
| Q3 FY26 | Q2 FY26 | Q3 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $4.98B | $4.71B | $5.51B | -9.5% |
| Operating income | $663.00M | $93.00M | $882.00M | -24.8% |
| Net income | $377.00M | -$310.00M | $574.00M | -34.3% |
| Diluted EPS | $1.37 | -$1.11 | $2.00 | |
| Operating cash flow | $776.00M | $671.00M | $1.22B | -36.3% |
| Capital expenditures | -$143.00M | -$125.00M | -$174.00M | |
| Free cash flow | $633.00M | $546.00M | $1.04B | -39.4% |
| Dividend per share | $1.05 | $1.05 | $1.04 |
| Q3 FY26 | Q3 FY25 | Year over year | |
|---|---|---|---|
| International Revenues | $1.90B | $2.33B | -18.3% |
| U.S. revenues | $3.08B | $3.18B | -3.1% |
| Revenue Growth (Currency-Neutral) | 4.4% | 9.9% | |
| BD Interventional revenues | $1.41B | $1.33B | +6.5% |
| BD Medical revenues | $1.68B | $2.93B | -42.8% |
| Adjusted Revenues Growth (Currency-Neutral) | 4.4% | 8.5% | |
| Organic revenue growth | 4.4% | 3% | |
| Base Revenues growth | 5.4% | 3% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Becton Dickinson (BDX) Q3 FY26 earnings: results and KPIs”, stockatlas.com/companies/BDX/earnings/2026-q3/, data as of 3 November 2026. Links to this page are welcome.
